Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Roche’s Flu MedKit Seeks “Alternate Pathway” For OTC Drugs

This article was originally published in The Tan Sheet

  • News

Executive Summary

The antiviral drug home stockpiling MedKit being shepherded by the Department of Health and Human Services could be the first product to test FDA's stated interest in "creative paths to access" that straddle or depart from the traditional choice of Rx or OTC status

You may also be interested in...



MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein

The spread of the 2009-H1N1 flu virus in the U.S. is not prompting FDA to accelerate work on a proposed program for home stockpiling of antiviral drugs, acting Commissioner Josh Sharfstein says

MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein

The spread of the 2009-H1N1 flu virus in the U.S. is not prompting FDA to accelerate work on a proposed program for home stockpiling of antiviral drugs, acting Commissioner Josh Sharfstein says

MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein

The spread of the 2009-H1N1 flu virus in the U.S. is not prompting FDA to accelerate work on a proposed program for home stockpiling of antiviral drugs, acting Commissioner Josh Sharfstein says

Table

View full table

Related Content

HBW Insight
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

ACA Ruling Is Double Whammy For PrEP Coverage, With Contraception And Vaccines Still At Risk

The Power Of The Public: Isotretinoin iPLEDGE Advisory Cmte. Is Case Study In An Effective OPH

Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing

iPLEDGE REMS: US FDA Advisory Cmte. Supports Relaxing Restrictions But Wants More Data

See All
UsernamePublicRestriction

Register

PS102363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By